Novartis, Wyeth Unit Spar Over ReFacto Patent

Law360, New York (March 5, 2009, 12:00 AM EST) -- Pharmaceutical giant Novartis AG has asserted its rights over two patents for several anti-hemophiliac treatments in an ongoing battle with Wyeth subsidiary Genetics Institute over who legally owns the formula for ReFacto, a drug related to recombinant anti-hemophiliac Factor VII.

Novartis' counterclaim against Genetics Institute, filed Tuesday in the U.S. District Court of Delaware, is the latest blow in a legal patent dispute that has lasted several years and gone through several courtrooms.

Novartis is asking the judge to dismiss Genetics Institutes' complaint with prejudice, on...
To view the full article, register now.